Valuation: Savara Inc.

Market Cap 1.25B 1.13B 1.05B 945M 1.78B 118B 1.84B 12.58B 4.99B 62.94B 4.69B 4.59B 200B P/E 2026 *
-7.68x
P/E 2027 * -11.8x
Enterprise Value 776M 703M 651M 587M 1.11B 73.19B 1.15B 7.82B 3.1B 39.1B 2.91B 2.85B 124B EV / Sales 2026 *
577x
EV / Sales 2027 * 11.4x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day-1.69%
1 week-3.93%
Current month-3.73%
1 month-2.52%
3 months-13.75%
6 months-11.95%
Current year-23.05%
1 week 4.58
Extreme 4.58
5.2
1 month 4.13
Extreme 4.13
5.2
Current year 4.13
Extreme 4.13
6.49
1 year 4.13
Extreme 4.13
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 59 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 73 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
24/9/26 Tax

Executive/Senior Manager

-29,323 0.0143%
15/7/26 Free

Chief Financial Officer

105,000 0.0512%
18/3/26 Exercice

Chief Financial Officer

850,254 0.4179%
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%-3.93%+7.91%+26.09% 1.25B
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.72%-0.35%+33.90%+164.74% 41B
Weighted average by Cap. -0.83%+0.19%+36.54%+154.85%

Financials

2026 *2027 *
Net sales 1.34M 1.22M 1.13M 1.02M 1.92M 127M 1.98M 13.54M 5.37M 67.72M 5.05M 4.94M 215M 78.5M 71.14M 65.8M 59.37M 112M 7.4B 116M 790M 313M 3.95B 295M 288M 12.55B
Net income -151M -137M -127M -114M -216M -14.27B -223M -1.52B -604M -7.62B -568M -556M -24.19B -97.06M -87.95M -81.35M -73.4M -138M -9.15B -143M -977M -388M -4.89B -364M -357M -15.52B
Net Debt -473M -429M -397M -358M -675M -44.63B -698M -4.77B -1.89B -23.84B -1.78B -1.74B -75.67B -352M -319M -295M -266M -501M -33.16B -519M -3.54B -1.4B -17.72B -1.32B -1.29B -56.23B
Projected Income Statement - Annual - Savara Inc.
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
13/11/26 USD 4.640 -1.69% 3,231,792
12/11/26 USD 4.720 -5.41% 4,297,079
11/11/26 USD 4.990 +1.42% 9,263,491
10/11/26 USD 4.920 -2.57% 1,730,116
09/11/26 USD 5.050 +4.55% 2,404,137
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Savara Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.640USD
Average target price
11.06USD
Spread / Average Target
+138.27%
  1. Stock Market
  2. Stocks
  3. SVRA Stock